PROK - Latest News
ProKidney Corp. (PROK), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $506.7M. Beta to the broader market is 1.75.
The article list below shows the most recent PROK headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PROK Headlines
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 15, 2026
ProKidney Corp. (PROK) came out with a quarterly loss of $0.
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com - May 15, 2026
WINSTON-SALEM, N. C.
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
defenseworld.net - Mar 27, 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which i
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
globenewswire.com - Mar 25, 2026
WINSTON-SALEM, N. C.
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
defenseworld.net - Mar 22, 2026
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are pre
How News Affects PROK Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PROK's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PROK news questions
- What is the latest PROK news headline?
- The most recent PROK headline (May 15, 2026) is "ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PROK news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PROK news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PROK options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.